E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
hospital acquired pneumonia caused by serotype O11 P.aeruginosa |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety, tolerability and repeated dose pharmacokinetics of three separate infusions of AERUMAB 11 every third day. |
|
E.2.2 | Secondary objectives of the trial |
1. To determine the most appropriate dosing schedule to maintain the trough plasma concentration of AERUMAB 11 above the supposed clinically and microbiologically effective level during the treatment period 2. To determine the most appropriate dose of AERUMAB 11 for future Phase II efficacy studies in P. aeruginosa HAP, as judged by the plasma concentration of AERUMAB 11 3. To identify the most appropriate assessment methodology in dosing to be used in future larger trials. 4. To seek possible evidence of therapeutic efficacy of AERUMAB 11 given in addition to standard care for HAP including the most appropriate choice of antibiotics according to local bacterial prevalence. 5. To correlate apparent clinical benefit with plasma concentrations of AERUMAB 11
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female ≥ 18 years of age 2. Female patients sterilised, hysterectomised, post-menopausal, or negative pregnancy test at screening evaluation. 3. Patients under intensive care management with hospital-acquired pneumonia 4. In intubated patients confirmed microbiological diagnosis of P. aeruginosa serotype O11 HAP by lower respiratory tract specimen (BAL or miniBAL) with equal or greater to 1x104 CFU/mL, or between 1x10^3 and 1x10^4 CFU/ml if the patient is under antibiotic treatment, and presence of a new or progressing pulmonary infiltrate, plus one of the three following criteria: a) fever greater than 38oC, b) WBC greater than 10,000/mm3, or c) purulent sputum
in non-intubated patients confirmed microbiological diagnosis of P. aeruginosa serotype O11 HAP by endotracheal aspirate (ETA) with equal or greater to 1x106 CFU/mL, and modified clinical pulmonary infection score (CPIS) higher than 6 points
Note: Serotyping may either be done with conventional microbiology/serology or PCR
5. Patient is expected to survive longer than 72 hours 6. Written informed consent provided by the patient or by the relatives or the designated trusted person
|
|
E.4 | Principal exclusion criteria |
1. Use of any investigational drug within 30 days preceding the first dose of AERUMAB 11, or planned use during the study and safety follow-up periods 2. Existence of any surgical or medical condition that might render the patient unduly susceptible to possible toxicity from the monoclonal antibody, including septic shock with unstable hemodynamics, as defined by a systolic blood pressure below 90 mmHg, despite vasopressor administration of epinephrine / norepinephrine at a dosage of greater than 0.1 μg/kg/min or dopamine at a dosage of greater 15 μg/kg/min), and presence of clinically relevant disseminated intravascular coagulation (overt DIC, as defined by a score of 5 or more using the scoring system proposed by the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the ISTH) [ ] 3. Patients with a known complement deficiency associated with systemic lupus erythematosus (SLE), paroxysmal nocturnal hemoglobinuria (PNH), hereditary angioedema (HAE), membranoproliferative glomerulonephritis, collagen vascular disease, autoimmune hepatitis, primary biliary cirrhosis, scleroderma, or recurrent Neisserial infections 4. Confirmed Human Immunodeficiency Virus (HIV) infection 5. Transplant patients and/or simultaneous treatment with systemic immuno-suppressive drugs. However, prednisone or prednisolone are allowed 6. Patients with a known liver function deficiency, e.g. associated with liver cirrhosis (Child Pugh B or C) or acute hepatitis 7. Administration of poly- or mono-immunoglobulins within the three months preceding the first dose of study drug or planned administration during the study period 8. Neutropenic patients (absolute neutrophil count < 1000 cells per microlitre)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To assess the safety, tolerability and repeated dose pharmacokinetics of three separate infusions of AERUMAB 11 every third day. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |